Squarepoint
TLSI icon

Squarepoint’s TriSalus Life Sciences TLSI Stock Holding History

Squarepoint’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,371
Closed -$310K – 4972
2025
Q4 		$310K Sell
44,371
-29,335
-40% -$164K ﹤0.01% 3586
2025
Q3 		$343K Buy
+73,706
New +$345K ﹤0.01% 3566

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Squarepoint's TLSI Position: Q1 2026 in Review

Squarepoint sold out of TriSalus Life Sciences (TLSI) in Q1 2026, closing a stake of 44,371 shares — an estimated $310K sold.

Squarepoint first reported a position in TLSI in Q3 2025 and held it in 2 quarters. The position peaked at $343K in Q3 2025. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

  • Squarepoint reported no remaining TriSalus Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 44,371 TriSalus Life Sciences shares in Q1 2026, an estimated $310K.
  • Squarepoint first reported a position in TriSalus Life Sciences in Q3 2025 and held it in 2 quarters.
  • Squarepoint's TriSalus Life Sciences position peaked at $343K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.